Boston Financial Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Boston Financial Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-5,695	Closed	-$262K	–	286
2016 Q3	$262K	Sell	5,695 -4,016	-41%	-$210K	0.02%	225
2016 Q2	$488K	Sell	9,711 -2,560	-21%	-$136K	0.04%	194
2016 Q1	$657K	Sell	12,271 -275	-2%	-$16.1K	0.1%	131
2015 Q4	$824K	Sell	12,546 -9,770	-44%	-$604K	0.12%	129
2015 Q3	$1.26M	Sell	22,316 -11,590	-34%	-$751K	0.18%	124
2015 Q2	$2M	Sell	33,906 -585	-2%	-$36.1K	0.26%	112
2015 Q1	$2.15M	Sell	34,491 -30	-0.1%	-$1.74K	0.27%	105
2014 Q4	$1.99M	Buy	34,521 +7,455	+28%	+$415K	0.25%	110
2014 Q3	$1.46M	Buy	27,066 +760	+3%	+$40.3K	0.19%	126
2014 Q2	$1.38M	Buy	26,306 +7,375	+39%	+$377K	0.18%	131
2014 Q1	$1M	Buy	18,931 +4,825	+34%	+$223K	0.13%	145
2013 Q4	$565K	Sell	14,106 -2,245	-14%	-$88.4K	0.08%	156
2013 Q3	$618K	Sell	16,351 -3,135	-16%	-$122K	0.09%	150
2013 Q2	$764K	Buy	+19,486	New	+$759K	0.12%	143

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Boston Financial Management's TEVA Position: Q4 2016 in Review

Boston Financial Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2016, closing a stake of 5,695 shares — an estimated $262K sold.

Boston Financial Management first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $2.15M in Q1 2015. 739 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Boston Financial Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2016 after selling out during the quarter.
Boston Financial Management sold 5,695 Teva Pharmaceutical Industries Limited shares in Q4 2016, an estimated $262K.
Boston Financial Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and held it in 14 quarters.
Boston Financial Management's Teva Pharmaceutical Industries Limited position peaked at $2.15M in Q1 2015.
739 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2016.

Based on Boston Financial Management's 13F filing for Q4 2016, filed 10 Feb 2017.